Hospira Reports Third-Quarter 20... (204.6$ 296.6(31.0)%Earnings Per Common S...)

Hospira Reports Third-Quarter 2011 Results

Date:10/26/2011

204.6$
296.6(31.0)%Earnings Per Common Share:Basic$
.23$
.79(31.3)%Diluted$
.21$
.75(30.9)%Weighted Average Common Shares Outstanding:Basic165.8165.50.2%Diluted168.7169.3(0.4)%Adjusted Gross Profit (1)(2)$
,219.0$
,277.9(4.6)%Adjusted Income From Operations (1)$
557.8$
42.3(13.2)%Adjusted Net Income (1)$
425.3$
429.5(1.0)%Adjusted Diluted Earnings Per Share (1)$
2.52$
2.54(0.8)%Statistics (as a % of net sales, except for income tax rate):GAAP Nine Months Ended September 30,Adjusted (1) Nine Months Ended September 30,2011201020112010Gross Profit (2)36.7%39.9%40.1%43.7%Income From Operations

8.8%15.9%18.3%22.0%Net Income6.7%10.1%14.0%14.7%Income Tax Rate

18.6%17.6%21.5%25.1%(1)

Adjusted financial measures exclude certain specified items as described and reconciled to comparable GAAP financial measures in the Reconciliation of GAAP to Non-GAAP Financial Measures contained in this press release.(2)

Gross profit is defined as Net sales less Cost of products sold. Adjusted gross profit excludes certain specified items, as indicated in the previous footnote.nm - Percentage change is not meaningful.Hospira, Inc.Reconciliation of GAAP to Non-GAAP Financial Measures(Unaudited)(dollars in millions, except for per share amounts)Three months ended September 30, 2011 Reconciliation of GAAP to Non-GAAP Financial Measures:Gross Profit (1) (Loss) Income

From Operations Net (Loss)

Income (2)Diluted EPSGAAP financial measures$
303.9$
(85.2)$
(88.9)$
(0.54)Specified item: Amortization and impairment of certain intangible assets (A)

19.234.423.40.14 Certain quality and product related charges (B)

36.736.722.90.14 Capacity expansion related charges (C)

1.51.51.00.01 Goodwill impairment (D)

SOURCE Hospira, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
Related medicine technology :

1. Hospira Announces Certain Preliminary Third-Quarter 2011 Results
2. Hospira to Host Conference Call for Third-Quarter 2011 Results
3. Hospira Announces Positive Results From Phase I U.S. Clinical Trial of Biosimilar Erythropoietin in Renal Patients
4. Hospira to Host 2011 Investor Day
5. Hospira to Present at the Morgan Stanley Global Healthcare Conference
6. Hospira Expands Board of Directors
7. Hospira Announces U.S. Approval of Solution Version of Gemcitabine Injection
8. Hospira Reports Second-Quarter 2011 Results
9. Hospira to Host Conference Call for Second-Quarter 2011 Results
10. Hospira Receives Health Canada Regulatory Approval for Symbiq™ Infusion System Software Upgrade
11. Hospira to Present at the Sanford C. Bernstein Twenty-Seventh Annual Strategic Decisions Conference 2011

Post Your Comments:

(Date:5/21/2013)... 21, 2013 Lakeland Industries, Inc. (NASDAQ: ... industrial protective clothing for industry, municipalities, healthcare and ... levels, today announced that the Company accepted a ... Credit Facility subject to certain terms and conditions ... However, no assurances can be given that this ...

(Date:5/21/2013)... May 21, 2013 Regulus Therapeutics Inc . ... discovery and development of innovative medicines targeting microRNAs, today ... Ph.D., Chief Operating Officer and Executive Vice President, Finance, ... 38th Annual Healthcare Conference on Wednesday, May 29, 2013 ... at the Westin Boston Waterfront Hotel. The ...

(Date:5/21/2013)... , May 21, 2013 Tom Daulton, CEO of Mammotome, ... of the Year by the Cincinnati ... was nominated by another local top executive who is also ... brand from Ethicon Endo-Surgery in March of 2010. Daulton will ... Awards program, presented by Huntington Bank, on May 22. ...

[0] Lakeland Industries, Inc. Reports Fiscal 2013 Fourth Quarter and Full Year Financial Results [0] Regulus to Present at Deutsche Bank 38th Annual Healthcare Conference [0] Tom Daulton, Mammotome CEO, Named ACG Dealmaker of the Year

... - VASTox plc (AIM: VOX), a leading,UK biotechnology ... of £400,000 by the Welsh Development Agency,(”WDA”) under ... 12 months, will support the research and development,work ... the unique skills and expertise of its scientists,based ...

... 2007 /PRNewswire-USNewswire/ -- The,following statement may be attributed ... Medical Research (CAMR): , "In the face of ... the stroke of his veto pen deliberately to ... well as endanger,the future health and well being ...

Cached Medicine Technology:Vastox Awarded £400,000 Grant to Support R&D at,Carbohydrate Chemistry Facility 2 Vastox Awarded £400,000 Grant to Support R&D at,Carbohydrate Chemistry Facility 3 President Bush Ignores America's Plea for Support of Stem Cell,Research 2

Vastox Awarded £400,000 Grant to Support R&D at,Carbohydrate Chemistry Facility President Bush Ignores America's Plea for Support of Stem Cell,Research

(Date:5/21/2013)... May 22, 2013 Feed additives have ... production industry value chain. Most of the feed additives ... injectable, pellets, liquids, and powders. There are variety of ... and concentrations depending upon the type of animal and ... vitamins that provide essential nutrition to the animal in ...

(Date:5/21/2013)... (PRWEB) May 21, 2013 Medical Ministry ... the prestigious 2013 Top-Rated Award by GreatNonprofits , the ... are excited to be named a Top-Rated 2013 Nonprofit,” says ... the dedication of our over 3000 Volunteers and Staff serving ... significant as it came from those that have seen our ...

(Date:5/21/2013)... on a large scale is the cornerstone of ... better outcomes, better value and better experience of ... patient-centered medical home model offers a viable solution ... of Health and Human Services, Agency for Healthcare ... more about the processes and determinants of successful ...

(Date:5/21/2013)... 21, 2013 Mecklenburg EMS Agency (Medic) ... hold a free Community Wellness Fair to educate the public ... will be held on Wednesday, May 22, 2013 from 4:00 ... (8100 Old Mallard Creek Road, Charlotte, NC 29262). ... and the Mecklenburg County Department of Social Services ...

(Date:5/21/2013)... May 2013, Paris, France: The Orsiro stent, which ... a biodegradable polymer, demonstrated non-inferiority to the Xience ... of in-stent late lumen loss at nine months ... at EuroPCR 2013 today. , The BIOFLOW-II substudy ... (OCT) to quantitatively assess neointimal hyperplasia and stent ...

Breaking Medicine News(10 mins):Health News:Protease Leads Feed Enzyme Market as Compared to Phytase & NSP Says New Research Report at ReportsnReports.com 2 Health News:Protease Leads Feed Enzyme Market as Compared to Phytase & NSP Says New Research Report at ReportsnReports.com 3 Health News:Protease Leads Feed Enzyme Market as Compared to Phytase & NSP Says New Research Report at ReportsnReports.com 4 Health News:Medical Ministry International Recognized as a 2013 Top-rated Nonprofit By GreatNonprofits.org 2 Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 2 Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 3 Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 4 Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 5 Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 6 Health News:Mecklenburg EMS Agency Teams Up with the YMCA of Greater Charlotte and Others to Educate the Public on Health Related Initiatives 2 Health News:Biodegradable stent proves non-inferior to drug-eluting stent 2

[0] Protease Leads Feed Enzyme Market as Compared to Phytase & NSP Says New Research Report at ReportsnReports.com [0] Medical Ministry International Recognized as a 2013 Top-rated Nonprofit By GreatNonprofits.org [0] AHRQ-funded journal supplement offers lessons on primary care practice transformation [0] Mecklenburg EMS Agency Teams Up with the YMCA of Greater Charlotte and Others to Educate the Public on Health Related Initiatives [0] Biodegradable stent proves non-inferior to drug-eluting stent

... 12 The Female Health Company (NYSE Alternext: ... (FDA) Obstetrics and Gynecology Devices Advisory Committee has unanimously voted ... is approvable with a single condition. , ... the product is approvable with the condition that the FC2 ...

... HOUSTON, Dec. 12 Access MediQuip, LLC, ... medical implantable device management,solutions to the healthcare ... industry,s first national contract for device benefit ... with WellPoint, Inc. to deliver,implantable device management ...

... and only approved peginterferon in combination with ribavirin for ... medical need , , ... SGP ) today announced that the U.S. Food ... PEGINTRON(TM) (peginterferon alfa-2b) and REBETOL(R) (ribavirin, USP) combination therapy ...

... director for the Pew Campaign on Human Health and ... U.S. Food and Drug Administration,s decision to reverse its ... animal agriculture: , , ... the increase in antibiotic-resistant infections - a fact long ...

... Hospitals Case Medical Center in conjunction with Sodexo Health Care ... Nosh 24/6 unit, the original certified kosher hot food vending ... machine in the state of Ohio, offering patients and their ... , , University Hospitals prides ...

... Life Insurance,Company (John Hancock) is reinforcing its commitment ... training requirements through an,affiliation with the ClearCert Clearinghouse. ... in the year and effective January 1, 2009,will ... , Since ...

Cached Medicine News:Health News:FDA Advisory Committee Votes Unanimously that FC2 Female Condom(R) is Approvable 2 Health News:FDA Advisory Committee Votes Unanimously that FC2 Female Condom(R) is Approvable 3 Health News:FDA Advisory Committee Votes Unanimously that FC2 Female Condom(R) is Approvable 4 Health News:FDA Advisory Committee Votes Unanimously that FC2 Female Condom(R) is Approvable 5 Health News:Access MediQuip and WellPoint Finalize First National Contract for Implantable Medical Devices 2 Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 2 Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 3 Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 4 Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 5 Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 6 Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 7 Health News:Statement From The Pew Charitable Trusts on the U.S. Food and Drug Administration's Reversal on Antibiotics Safeguards in Animal Farming 2 Health News:University Hospitals Case Medical Center Installs First Hot Kosher Vending Machine 2 Health News:University Hospitals Case Medical Center Installs First Hot Kosher Vending Machine 3 Health News:John Hancock Expands LTC Training Effort with ClearCert High Usage By Producers and Streamlines Process for Insurers 2 Health News:John Hancock Expands LTC Training Effort with ClearCert High Usage By Producers and Streamlines Process for Insurers 3

FDA Advisory Committee Votes Unanimously that FC2 Female Condom(R) is Approvable Access MediQuip and WellPoint Finalize First National Contract for Implantable Medical Devices Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C Statement From The Pew Charitable Trusts on the U.S. Food and Drug Administration's Reversal on Antibiotics Safeguards in Animal Farming University Hospitals Case Medical Center Installs First Hot Kosher Vending Machine John Hancock Expands LTC Training Effort with ClearCert High Usage By Producers and Streamlines Process for Insurers

... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...

... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...

Medicine Products:

Dapsone, Serum or Plasma Dalmane D-lysergic Acid Diethylamide, Urine D, 1-25 Dihydroxy, Vitamin